671 related articles for article (PubMed ID: 22491770)
1. Epithelial cell responses to infection with human papillomavirus.
Stanley MA
Clin Microbiol Rev; 2012 Apr; 25(2):215-22. PubMed ID: 22491770
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to human papilloma viruses.
Stanley MA
Indian J Med Res; 2009 Sep; 130(3):266-76. PubMed ID: 19901436
[TBL] [Abstract][Full Text] [Related]
3. Host responses to infection with human papillomavirus.
Stanley MA; Sterling JC
Curr Probl Dermatol; 2014; 45():58-74. PubMed ID: 24643178
[TBL] [Abstract][Full Text] [Related]
4. HPV - immune response to infection and vaccination.
Stanley M
Infect Agent Cancer; 2010 Oct; 5():19. PubMed ID: 20961432
[TBL] [Abstract][Full Text] [Related]
5. High-risk HPV oncoproteins E6 and E7 and their interplay with the innate immune response: Uncovering mechanisms of immune evasion and therapeutic prospects.
Lo Cigno I; Calati F; Girone C; Catozzo M; Gariglio M
J Med Virol; 2024 Jun; 96(6):e29685. PubMed ID: 38783790
[TBL] [Abstract][Full Text] [Related]
6. Immunobiology of HPV and HPV vaccines.
Stanley M
Gynecol Oncol; 2008 May; 109(2 Suppl):S15-21. PubMed ID: 18474288
[TBL] [Abstract][Full Text] [Related]
7. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
8. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review.
Graham SV
Clin Sci (Lond); 2017 Sep; 131(17):2201-2221. PubMed ID: 28798073
[TBL] [Abstract][Full Text] [Related]
9. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
10. Carcinogenesis Associated with Human Papillomavirus Infection. Mechanisms and Potential for Immunotherapy.
Vonsky M; Shabaeva M; Runov A; Lebedeva N; Chowdhury S; Palefsky JM; Isaguliants M
Biochemistry (Mosc); 2019 Jul; 84(7):782-799. PubMed ID: 31509729
[TBL] [Abstract][Full Text] [Related]
11. Host control of human papillomavirus infection and disease.
Doorbar J
Best Pract Res Clin Obstet Gynaecol; 2018 Feb; 47():27-41. PubMed ID: 28919159
[TBL] [Abstract][Full Text] [Related]
12. Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer.
Sasagawa T; Takagi H; Makinoda S
J Infect Chemother; 2012 Dec; 18(6):807-15. PubMed ID: 23117294
[TBL] [Abstract][Full Text] [Related]
13. [Immune response in cervical cancer. Strategies for the development of therapeutic vaccines].
Mora-García ML; Monroy-García A
Rev Med Inst Mex Seguro Soc; 2015; 53 Suppl 2():S206-11. PubMed ID: 26462518
[TBL] [Abstract][Full Text] [Related]
14. Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.
Yang R; Wheeler CM; Chen X; Uematsu S; Takeda K; Akira S; Pastrana DV; Viscidi RP; Roden RB
J Virol; 2005 Jun; 79(11):6741-50. PubMed ID: 15890912
[TBL] [Abstract][Full Text] [Related]
15. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination.
Smyth LJ; Van Poelgeest MI; Davidson EJ; Kwappenberg KM; Burt D; Sehr P; Pawlita M; Man S; Hickling JK; Fiander AN; Tristram A; Kitchener HC; Offringa R; Stern PL; Van Der Burg SH
Clin Cancer Res; 2004 May; 10(9):2954-61. PubMed ID: 15131030
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.
Baldwin PJ; van der Burg SH; Boswell CM; Offringa R; Hickling JK; Dobson J; Roberts JS; Latimer JA; Moseley RP; Coleman N; Stanley MA; Sterling JC
Clin Cancer Res; 2003 Nov; 9(14):5205-13. PubMed ID: 14614000
[TBL] [Abstract][Full Text] [Related]
17. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results.
Schiller JT; Castellsagué X; Villa LL; Hildesheim A
Vaccine; 2008 Aug; 26 Suppl 10(Suppl 10):K53-61. PubMed ID: 18847557
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
19. HPV: from infection to cancer.
Stanley MA; Pett MR; Coleman N
Biochem Soc Trans; 2007 Dec; 35(Pt 6):1456-60. PubMed ID: 18031245
[TBL] [Abstract][Full Text] [Related]
20. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
